These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 34444777)

  • 1. Omega-3 Polyunsaturated Fatty Acid: A Pharmaco-Nutraceutical Approach to Improve the Responsiveness to Ursodeoxycholic Acid.
    Thérien A; Cieślak A; Verreault M; Perreault M; Trottier J; Gobeil S; Vohl MC; Barbier O
    Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of ursodeoxycholic acid on the relative expression of the lipid metabolism genes in mouse cholesterol gallstone models.
    Fan N; Meng K; Zhang Y; Hu Y; Li D; Gao Q; Wang J; Li Y; Wu S; Cui Y
    Lipids Health Dis; 2020 Jul; 19(1):158. PubMed ID: 32615989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells.
    He H; Mennone A; Boyer JL; Cai SY
    Hepatology; 2011 Feb; 53(2):548-57. PubMed ID: 21274875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-3 Polyunsaturated Fatty Acids Stimulate Bile Acid Detoxification in Human Cell Models.
    Cieślak A; Trottier J; Verreault M; Milkiewicz P; Vohl MC; Barbier O
    Can J Gastroenterol Hepatol; 2018; 2018():6031074. PubMed ID: 29850457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
    Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
    Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
    Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
    J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting Endoplasmic Reticulum (ER) Stress Induced by Disturbed Flow.
    Chung J; Kim KH; Lee SC; An SH; Kwon K
    Mol Cells; 2015 Oct; 38(10):851-8. PubMed ID: 26442866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
    Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
    Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
    van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
    J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of ursodeoxycholic acid in patients with liver disease.
    Angulo P
    Curr Gastroenterol Rep; 2002 Feb; 4(1):37-44. PubMed ID: 11825540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile Acids as Signaling Molecules: Role of Ursodeoxycholic Acid in Cholestatic Liver Disease.
    Cifuentes-Silva E; Cabello-Verrugio C
    Curr Protein Pept Sci; 2024; 25(3):206-214. PubMed ID: 37594109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of cholestatic liver diseases].
    Gatzen M; Pausch J
    Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice.
    Cai SY; Mennone A; Soroka CJ; Boyer JL
    J Pharmacol Exp Ther; 2014 Apr; 349(1):94-8. PubMed ID: 24492652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.
    Jazrawi RP; de Caestecker JS; Goggin PM; Britten AJ; Joseph AE; Maxwell JD; Northfield TC
    Gastroenterology; 1994 Jan; 106(1):134-42. PubMed ID: 8276175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
    Trauner M; Fickert P; Halilbasic E; Moustafa T
    Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bile acids in liver diseases--current indications].
    Stiehl A
    Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
    Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
    Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapeutical indications of ursodeoxycholic acid.
    Copaci I; Micu L; Iliescu L; Voiculescu M
    Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.
    Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Pojer C; Zenz R; Lammert F; Stieger B; Meier PJ; Zatloukal K; Denk H; Trauner M
    Gastroenterology; 2001 Jul; 121(1):170-83. PubMed ID: 11438506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.